{
  "id": "cluster_3_doc4",
  "content": "NeuroCare Quarterly publication (September 2023 edition) highlights improved outcomes with combination immunotherapy for TP53-positive glioblastoma patients. Study cohort included 127 patients from 6 centers, including Ridgeview Medical Center. Median progression-free survival increased by 3.2 months compared to standard therapy.",
  "metadata": {
    "format": "research_note"
  }
}